Bioversys AG (BIOV) — Working Capital to Net Assets Ratio

Latest as of December 2025: 135.4%

Bioversys AG (BIOV) has a Working Capital to Net Assets ratio of 135.4% as of December 2025. Working capital of CHF80.97 Million (current assets of CHF89.87 Million minus current liabilities of CHF8.90 Million) is measured against net assets of CHF59.81 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See BIOV defensive interval ratio to measure how many days the company can operate on defensive assets alone.

WC/NA Ratio

135.4%
Working Capital / Net Assets

Working Capital

CHF80.97 Million
CHF

Current Assets

CHF89.87 Million
CHF

Current Liabilities

CHF8.90 Million
CHF

Bioversys AG Working Capital to Net Assets (2024–2025)

This chart shows how Bioversys AG's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the ratio stands at 135.4%, reflecting working capital of CHF80.97 Million against net assets of CHF59.81 Million CHF. For the complete balance sheet picture, see BIOV current and non-current assets.

Annual Working Capital to Net Assets for Bioversys AG (2024–2025)

The table below presents the year-by-year Working Capital to Net Assets ratio for Bioversys AG from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check BIOV financial resilience to evaluate the company's liquid asset resilience ratio.

Year WC/NA Ratio Working Capital (CHF) Net Assets Current Assets Current Liabilities Change (pp)
2025 135.4% CHF80.97 Million CHF59.81 Million CHF89.87 Million CHF8.90 Million ▼ -96.1 pp
2024 231.5% CHF24.73 Million CHF10.68 Million CHF34.40 Million CHF9.67 Million
pp = percentage points